Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

No Mid-term Advantage by Electrochemical Deposition of Hydroxyl-apatite in Cementless Femoral Stems. 5-year RSA and DXA Results From a Randomized Controlled Trial

NCT02321683 is registered in ClinicalTrials.gov with Lars Nordsletten as lead sponsor.

NCT NCT02321683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02321683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
No Mid-term Advantage by Electrochemical Deposition of Hydroxyl-apatite in Cementless Femoral Stems. 5-year RSA and DXA Results From a Randomized Controlled Trial
Lead sponsor
Lars Nordsletten
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2003
Completion date
December 31, 2008
Enrollment
55 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hip osteoarthritis